

Improving the Care of Mothers, Infants and Families Impacted by Perinatal Opioid Use: A Massachusetts Statewide Initiative



Key Metrics Aggregate Statewide Report January 2017- September 2024

Please do not share

PNQIN Statewide Report 2023-September

Table of Contents

Statewide Descriptive Demographics and Reporting by Quarter	3
Maternal Metrics	3
--Medications for Opioid Use Disorder in Mothers of Opioid-Exposed Newborns	4
--Exclusive Medications for Opioid Use Disorder in Mothers of Opioid-Exposed Newborns	5
--Illicit Opioid Use in Mothers	6
--Antenatal Consulting Use in Mothers	7
Newborn Care Metrics	7
--Pharmacologic Therapy for NOWS	8
--Non-Pharmacologic Therapy for NOWS: Skin-to-Skin Contact.....	9
--Non-Pharmacologic Therapy for NOWS: Rooming-in	10
--Non-Pharmacologic Therapy for NOWS: Rooming-in After Maternal Discharge	11
--Breastmilk Eligibility in Opioid-Exposed Newborns Per Hospital Guidelines	12
--Mother's Milk Use Among Eligible Opioid-Exposed Newborns.....	13
--Mother's Milk Use in All Opioid-Exposed Newborns.....	14
--Mother's Milk Use at Discharge Among Eligible Opioid-Exposed Newborns	15
--Mother's Milk in All Opioid-Exposed Newborns at Discharge.....	16
--Length of Hospital Stay Among Term newborns	17
--Length of Hospital Stay Among Term newborns when Pharmacologic Therapy is Not Given	18
--Length of Stay Among Term newborns when Pharmacologic Therapy is Given	19
--Length of Pharmacologic Therapy	20
--Location of Care Term newborns	21
Post-Discharge Care Metrics	21
--Plans of Safe Care	22
--Early Intervention Referral	23
--Department of Children and Families Referral.....	24
--Discharged Home to Parent	25
Appendix	26

Notes

This report summarizes performance for the PNQIN statewide initiative to improve the care of families impacted by perinatal opioid use and infants at risk for Neonatal Opioid Withdrawal Syndrome (NOWS). Key metrics from the initiative were selected for inclusion in this report, and the report will be updated monthly.

Participating hospitals are asked to submit data on infants at risk for NOWS due to possible or known in-utero opioid exposure. Infants at risk for withdrawal only for postnatal opioid exposure are not included. There are no gestational age exclusions, although some measures are reported only for term infants.

Each measure is presented as a control chart that shows aggregate performance over time for all hospitals submitting data. All infants in the database from January 2017 to the current month are included. In each control chart, the center line reflects overall performance for the state, and the blue shaded area extends to three control limits from the center line. Center lines are established based on the first 20 data points; standard rules are then used to identify special cause variation and shift the center line accordingly.

Each measure is also presented as a comparison chart, showing performance across hospitals. For the comparison charts, performance over the current 12 months is shown. Hospitals with less than 5 infants in the database this period are not included. Results shown in this report may change as additional data is entered by participating centers.

IHI Control Chart Rules

1=One point outside the control limits

2=Eight points in a row on one side of the central line


3=Six points in a row steadily increasing or steadily decreasing

5=Two out of three points in a row in Zone A or beyond

7=Fifteen points in a row in Zone C on either or both sides of the central line

PNQIN Statewide Report 2023-September

Statewide Descriptive Demographics and Reporting by Month



Statewide Demographics

All Infants born beginning 1/1/17

	Statewide	
Sample Size	4921	--
Mother and infant characteristics	N	%
Maternal Race/Ethnicity		
Hispanic	405	8.2
Non-Hispanic black	197	4.0
Non-Hispanic white	4032	81.9
Other/unknown	287	5.8
Infant gender		
Male	2529	51.4
Female	2371	48.2
Unknown	21	0.4
Location of birth		
Inborn	4658	94.7
Outborn	242	4.9
Unknown	21	0.4
Term >= 37 weeks		
Yes	3976	80.8
Gestational age, weeks		
Mean SD	37.9	2.2

PNQIN Statewide Report 2023-September



Maternal Care Metrics

Medications for Opioid Use Disorder in Mothers of Opioid-Exposed Newborns

Numerator: Number of newborns exposed to prescribed methadone or prescribed buprenorphine during pregnancy

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better





Maternal Care Metrics

Exclusive Medications for Opioid Use Disorder in Mothers of Opioid-Exposed Newborns

Numerator: Number of newborns exposed exclusively to prescribed methadone or prescribed buprenorphine during pregnancy

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better



Maternal Care Metrics



Illicit Opioid Use in Mothers

Numerator: Number of newborns exposed to any illicit opioids

Illicit opioids defined as methadone, buprenorphine, fentanyl, or other opioids from illicit or unknown source, or heroin

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, lower is better





Maternal Care Metrics

Antenatal or Prenatal Consult Prior to Birth

Numerator: Number of mothers who have received an antenatal/prenatal consult

Denominator: All mothers of newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better





Newborn Care Metrics

Pharmacologic Therapy for NOWS

Numerator: Number of newborns requiring a pharmacologic agent for treatment of NOWS

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, lower is better





Newborn Care Metrics

Non-Pharmacologic Therapy for NOWS: Skin-to-Skin Contact

Numerator: Number of newborns receiving skin-to-skin contact any time during first 24 hours of life

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better





Newborn Care Metrics

Non-Pharmacologic Therapy for NOWS: Rooming-in

Numerator: Number of newborns who >roomed-in> for at least 1 night prior to maternal discharge

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better





Newborn Care Metrics

Non-Pharmacologic Therapy for NOWS: Rooming-in After Maternal Discharge

Numerator: Number of newborns who roomed-in after maternal discharge

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better





Newborn Care Metrics

Breastmilk Eligibility in Opioid-Exposed Newborns Per Hospital Guidelines

Numerator: Number of newborns who were eligible to receive mother's milk per hospital policy

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure



Goal: No specific numeric target



Newborn Care Metrics

Mother's Milk Use Among Eligible Opioid-Exposed Newborns

Numerator: Number of newborns who received mother's milk anytime during hospitalization
 Denominator: All newborns at risk for NOWS who were eligible for mother's milk per hospital policy
 Goal: In general, higher is better





Newborn Care Metrics

Mother's Milk Use in All Opioid-Exposed Newborns

Numerator: Number of newborns who received mother's milk at any time during hospitalization

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better





Newborn Care Metrics

Mother's Milk Use at Discharge Among Eligible Opioid-Exposed Newborns

Numerator: Number of newborns who received mother's milk within 24 hours of discharge

Denominator: All newborns at risk for NOWS who were eligible for mother's milk per hospital policy

Goal: In general, higher is better





Newborn Care Metrics

Mother's Milk in All Opioid-Exposed Newborns at Discharge

Numerator: Number of newborns who received mother's own milk within 24 hours of discharge

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better





Newborn Care Metrics

Length of Hospital Stay Among Term Newborns

Numerator: Total number of days term newborns spent in hospital

Denominator: All newborns with gestational age 37 weeks or greater at risk for NOWS due to in-utero opioid exposure

Goal: No specific numeric target





Newborn Care Metrics

Length of Hospital Stay Among Term Newborns when Pharmacologic Therapy is Not Given

Numerator: Total number of days newborns spent in hospital when pharmacologic agents were not used to treat NOWS

Denominator: Newborns with gestational age 37 weeks or greater at risk for NOWS who did not receive pharmacologic therapy for NOWS

Goal: No specific numeric target





Newborn Care Metrics

Length of Stay Among Term Newborns when Pharmacologic Therapy is Given

Numerator: Total number of days newborns spent in hospital when pharmacologic agents were used to treat NOWS

Denominator: Newborns with gestational age 37 weeks or greater at risk for NOWS who did receive pharmacologic therapy for NOWS

Goal: No specific numeric target





Newborn Care Metrics

Length of Pharmacologic Therapy Among Term Infants

Numerator: Total number of days newborns spent in hospital when pharmacologic agents were used to treat NOWS

Denominator: Newborns with gestational age 37 weeks or greater at risk for NOWS who did receive pharmacologic therapy for NOWS

Goal: No specific numeric target





Newborn Care Metrics

Higher Level of Care Among Term Newborns

Numerator: Number of newborns who received care in Level 2 Nursery (SCN) or Level 3 Nursery (NICU)

Denominator: All newborns with gestational age 37 weeks or greater at risk for NOWS due to in-utero opioid exposure

Goal: In general, lower is better





Post-Discharge Care Metrics

Plan of Safe Care Prior to Discharge

Numerator: Number of newborns with Plan of Safe Care in place prior to discharge

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better





Post-Discharge Care Metrics

Referral to Early Intervention

Numerator: Number of newborns who received a referral to Early Intervention prior to discharge

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better





Post-Discharge Care Metrics

Referral to Department of Children and Families

Numerator: Number of newborns that were referred to the Department of Children and Families during hospitalization (i.e., 51A)

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: No specific numeric target





Post-Discharge Care Metrics

Discharge Home with Biologic Parent

Numerator: Number of newborns who were discharged home with their biologic parent

Denominator: All newborns at risk for NOWS due to in-utero opioid exposure

Goal: In general, higher is better



Appendix

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
Any Medication Assisted Therapy	2017-Q1	318	255	80.2	Exclusive Medication Assisted Therapy	2017-Q1	318	183	57.5
	2017-Q2	266	212	79.7		2017-Q2	266	172	64.7
	2017-Q3	260	203	78.1		2017-Q3	260	160	61.5
	2017-Q4	290	232	80.0		2017-Q4	290	178	61.4
	2018-Q1	262	207	79.0		2018-Q1	262	154	58.8
	2018-Q2	217	175	80.6		2018-Q2	217	136	62.7
	2018-Q3	205	163	79.5		2018-Q3	205	117	57.1
	2018-Q4	212	178	84.0		2018-Q4	212	137	64.6
	2019-Q1	227	186	81.9		2019-Q1	227	135	59.5
	2019-Q2	213	178	83.6		2019-Q2	213	121	56.8
	2019-Q3	222	188	84.7		2019-Q3	222	137	61.7
	2019-Q4	196	165	84.2		2019-Q4	196	117	59.7
	2020-Q1	184	154	83.7		2020-Q1	184	102	55.4
	2020-Q2	181	151	83.4		2020-Q2	181	108	59.7
	2020-Q3	178	140	78.7		2020-Q3	178	100	56.2
	2020-Q4	173	143	82.7		2020-Q4	173	98	56.6
	2021-Q1	148	106	71.6		2021-Q1	148	76	51.4
	2021-Q2	126	92	73		2021-Q2	126	62	49.2
	2021-Q3	125	104	83.2		2021-Q3	125	73	58.4
	2021-Q4	119	102	85.7		2021-Q4	119	71	59.7
	2022-Q1	106	82	77.4		2022-Q1	106	58	54.7
	2022-Q2	98	76	77.6		2022-Q2	98	57	58.2
	2022-Q3	94	75	79.8		2022-Q3	94	55	58.5
	2022-Q4	79	60	75.9		2022-Q4	79	46	58.2
	2023-Q1	91	76	83.5		2023-Q1	91	51	56
	2023-Q2	83	70	84.3		2023-Q2	83	44	53
	2023-Q3	76	67	88.2		2023-Q3	76	42	55.3
	2023-Q4	54	43	79.6		2023-Q4	54	30	55.6
	2024-Q1	52	44	84.6		2024-Q1	52	25	48.1
	2024-Q2	43	38	88.4		2024-Q2	43	26	60.5
	2024-Q3	23	15	65.2		2024-Q3	23	10	43.5

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
Illegal Opioids	2017-Q1	318	107	33.6	Antenatal Consult MC	2017-Q1	316	139	44.0
	2017-Q2	266	75	28.2		2017-Q2	264	94	35.6
	2017-Q3	260	76	29.2		2017-Q3	260	102	39.2
	2017-Q4	290	90	31.0		2017-Q4	290	142	49.0
	2018-Q1	262	87	33.2		2018-Q1	261	116	44.4
	2018-Q2	217	63	29.0		2018-Q2	216	101	46.8
	2018-Q3	205	70	34.1		2018-Q3	205	73	35.6
	2018-Q4	212	60	28.3		2018-Q4	208	104	50.0
	2019-Q1	227	73	32.2		2019-Q1	227	89	39.2
	2019-Q2	213	83	39.0		2019-Q2	211	96	45.5
	2019-Q3	222	70	31.5		2019-Q3	219	81	37.0
	2019-Q4	196	69	35.2		2019-Q4	194	81	41.8
	2020-Q1	184	70	38.0		2020-Q1	184	69	37.5
	2020-Q2	181	65	35.9		2020-Q2	179	57	31.8
	2020-Q3	178	64	36.0		2020-Q3	177	71	40.1
	2020-Q4	173	68	39.3		2020-Q4	171	74	43.3
	2021-Q1	148	59	39.9		2021-Q1	147	59	40.1
	2021-Q2	126	53	42.1		2021-Q2	126	64	50.8
	2021-Q3	125	44	35.2		2021-Q3	120	61	50.8
	2021-Q4	119	44	37.0		2021-Q4	115	41	35.7
	2022-Q1	106	38	35.8		2022-Q1	104	48	46.2
	2022-Q2	98	36	36.7		2022-Q2	94	44	46.8
	2022-Q3	94	31	33.0		2022-Q3	93	44	47.3
	2022-Q4	79	28	35.4		2022-Q4	79	33	41.8
	2023-Q1	91	33	36.3		2023-Q1	91	43	47.3
	2023-Q2	83	34	41.0		2023-Q2	82	34	41.5
	2023-Q3	76	32	42.1		2023-Q3	76	32	42.1
	2023-Q4	54	20	37.0		2023-Q4	51	31	60.8
	2024-Q1	52	24	46.2		2024-Q1	51	31	60.8
	2024-Q2	43	14	32.6		2024-Q2	42	22	52.4
	2024-Q3	23	10	43.5		2024-Q3	22	8	36.4

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
Pharmaceutical Therapy	2017-Q1	318	190	59.7	Skin to Skin	2017-Q1	317	194	61.2
	2017-Q2	266	110	41.4		2017-Q2	265	171	64.5
	2017-Q3	260	135	51.9		2017-Q3	259	182	70.3
	2017-Q4	290	143	49.3		2017-Q4	290	217	74.8
	2018-Q1	260	147	56.5		2018-Q1	262	196	74.8
	2018-Q2	217	91	41.9		2018-Q2	217	169	77.9
	2018-Q3	202	82	40.6		2018-Q3	202	145	71.8
	2018-Q4	210	63	30.0		2018-Q4	208	157	75.5
	2019-Q1	222	82	36.9		2019-Q1	226	159	70.4
	2019-Q2	211	69	32.7		2019-Q2	213	174	81.7
	2019-Q3	220	73	33.2		2019-Q3	219	169	77.2
	2019-Q4	195	69	35.4		2019-Q4	196	161	82.1
	2020-Q1	182	58	31.9		2020-Q1	184	127	69.0
	2020-Q2	180	66	36.7		2020-Q2	181	136	75.1
	2020-Q3	174	52	29.9		2020-Q3	176	124	70.5
	2020-Q4	172	68	39.5		2020-Q4	173	136	78.6
	2021-Q1	148	50	33.8		2021-Q1	148	108	73
	2021-Q2	126	54	42.9		2021-Q2	125	94	75.2
	2021-Q3	121	40	33.1		2021-Q3	121	101	83.5
	2021-Q4	117	46	39.3		2021-Q4	116	94	81
	2022-Q1	104	40	38.5		2022-Q1	105	83	79
	2022-Q2	97	43	44.3		2022-Q2	95	78	82.1
	2022-Q3	94	30	31.9		2022-Q3	93	75	80.6
	2022-Q4	79	27	34.2		2022-Q4	78	58	74.4
	2023-Q1	91	36	39.6		2023-Q1	90	66	73.3
	2023-Q2	83	35	42.2		2023-Q2	83	68	81.9
	2023-Q3	76	27	35.5		2023-Q3	75	72	96
	2023-Q4	54	21	38.9		2023-Q4	54	51	94.4
	2024-Q1	51	20	39.2		2024-Q1	52	42	80.8
	2024-Q2	43	12	27.9		2024-Q2	43	35	81.4
	2024-Q3	22	4	18.2		2024-Q3	22	16	72.7

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
Rooming In	2017-Q1	318	250	78.6					
	2017-Q2	266	200	75.2					
	2017-Q3	260	203	78.1					
	2017-Q4	290	227	78.3					
	2018-Q1	262	197	75.2					
	2018-Q2	216	166	76.9					
	2018-Q3	202	145	71.8					
	2018-Q4	209	166	79.4					
	2019-Q1	226	182	80.5	Rooming In After Discharge NC	2019-Q1	211	126	59.7
	2019-Q2	213	162	76.1		2019-Q2	212	123	58.0
	2019-Q3	220	175	79.5		2019-Q3	220	123	55.9
	2019-Q4	195	157	80.5		2019-Q4	195	114	58.5
	2020-Q1	183	131	71.6		2020-Q1	184	91	49.5
	2020-Q2	181	135	74.6		2020-Q2	180	90	50.0
	2020-Q3	177	140	79.1		2020-Q3	176	87	49.4
	2020-Q4	173	132	76.3		2020-Q4	171	83	48.5
	2021-Q1	148	106	71.6		2021-Q1	147	81	55.1
	2021-Q2	126	91	72.2		2021-Q2	126	62	49.2
	2021-Q3	122	91	74.6		2021-Q3	121	74	61.2
	2021-Q4	116	86	74.1		2021-Q4	117	67	57.3
	2022-Q1	106	80	75.5		2022-Q1	105	67	63.8
	2022-Q2	96	65	67.7		2022-Q2	96	49	51.0
	2022-Q3	93	68	73.1		2022-Q3	93	48	51.6
	2022-Q4	79	59	74.7		2022-Q4	79	45	57.0
	2023-Q1	90	56	62.2		2023-Q1	91	42	46.2
	2023-Q2	83	49	59		2023-Q2	83	39	47.0
	2023-Q3	76	62	81.6		2023-Q3	75	49	65.3
	2023-Q4	54	43	79.6		2023-Q4	54	35	64.8
	2024-Q1	52	32	61.5		2024-Q1	52	24	46.2
	2024-Q2	43	30	69.8		2024-Q2	43	22	51.2
	2024-Q3	23	20	87		2024-Q3	23	16	69.6

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
Eligible for MOM	2017-Q1	317	207	65.3					
	2017-Q2	266	167	62.8					
	2017-Q3	259	166	64.1					
	2017-Q4	290	193	66.6					
	2018-Q1	257	175	68.1					
	2018-Q2	207	148	71.5					
	2018-Q3	197	130	66.0					
	2018-Q4	204	151	74.0					
	2019-Q1	221	158	71.5					
	2019-Q2	208	130	62.5					
	2019-Q3	219	143	65.3					
	2019-Q4	196	131	66.8					
	2020-Q1	184	126	68.5					
	2020-Q2	181	118	65.2					
	2020-Q3	177	118	66.7					
	2020-Q4	173	116	67.1					
	2021-Q1	147	98	66.7					
	2021-Q2	126	86	68.3					
	2021-Q3	121	77	63.6					
	2021-Q4	118	76	64.4					
	2022-Q1	104	69	66.3					
	2022-Q2	95	64	67.4					
	2022-Q3	93	64	68.8					
	2022-Q4	79	56	70.9					
	2023-Q1	89	53	59.6					
	2023-Q2	82	53	64.6					
	2023-Q3	76	52	68.4					
	2023-Q4	54	39	72.2					
	2024-Q1	52	32	61.5					
	2024-Q2	43	30	69.8					
	2024-Q3	23	11	47.8					

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
MOM any (Eligible Only)	2017-Q1	207	155	74.9	MOM any (Full Cohort)	2017-Q1	318	167	52.5
	2017-Q2	167	138	82.6		2017-Q2	265	151	57.0
	2017-Q3	166	125	75.3		2017-Q3	260	130	50.0
	2017-Q4	193	151	78.2		2017-Q4	290	169	58.3
	2018-Q1	175	137	78.3		2018-Q1	261	144	55.2
	2018-Q2	147	115	78.2		2018-Q2	216	128	59.3
	2018-Q3	130	96	73.8		2018-Q3	203	109	53.7
	2018-Q4	151	118	78.1		2018-Q4	211	129	61.1
	2019-Q1	157	123	78.3		2019-Q1	225	130	57.8
	2019-Q2	130	98	75.4		2019-Q2	213	107	50.2
	2019-Q3	143	114	79.7		2019-Q3	221	124	56.1
	2019-Q4	130	106	81.5		2019-Q4	195	110	56.4
	2020-Q1	126	98	77.8		2020-Q1	184	99	53.8
	2020-Q2	118	86	72.9		2020-Q2	181	87	48.1
	2020-Q3	118	79	66.9		2020-Q3	177	82	46.3
	2020-Q4	116	87	75.0		2020-Q4	173	87	50.3
	2021-Q1	98	76	77.6		2021-Q1	147	78	53.1
	2021-Q2	86	65	75.6		2021-Q2	126	69	54.8
	2021-Q3	76	61	80.3		2021-Q3	121	64	52.9
	2021-Q4	76	63	82.9		2021-Q4	118	66	55.9
	2022-Q1	69	41	59.4		2022-Q1	106	43	40.6
	2022-Q2	64	50	78.1		2022-Q2	97	50	51.5
	2022-Q3	64	50	78.1		2022-Q3	92	53	57.6
	2022-Q4	55	43	78.2		2022-Q4	78	44	56.4
	2023-Q1	52	39	75.0		2023-Q1	89	42	47.2
	2023-Q2	53	37	69.8		2023-Q2	83	38	45.8
	2023-Q3	52	39	75.0		2023-Q3	75	39	52
	2023-Q4	39	26	66.7		2023-Q4	54	26	48.1
	2024-Q1	32	28	87.5		2024-Q1	52	29	55.8
	2024-Q2	30	24	80.0		2024-Q2	43	24	55.8
	2024-Q3	10	8	80.0		2024-Q3	22	9	40.9

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
MOM discharge (Eligible Only)	2017-Q1	207	120	58.0	MOM discharge (Full Cohort)	2017-Q1	318	127	39.9
	2017-Q2	166	117	70.5		2017-Q2	265	123	46.4
	2017-Q3	166	96	57.8		2017-Q3	260	98	37.7
	2017-Q4	192	126	65.6		2017-Q4	289	136	47.1
	2018-Q1	175	113	64.6		2018-Q1	261	119	45.6
	2018-Q2	148	87	58.8		2018-Q2	215	95	44.2
	2018-Q3	129	86	66.7		2018-Q3	203	92	45.3
	2018-Q4	151	103	68.2		2018-Q4	211	111	52.6
	2019-Q1	158	105	66.5		2019-Q1	226	108	47.8
	2019-Q2	130	74	56.9		2019-Q2	213	81	38.0
	2019-Q3	142	99	69.7		2019-Q3	220	107	48.6
	2019-Q4	129	89	69.0		2019-Q4	194	93	47.9
	2020-Q1	126	93	73.8		2020-Q1	184	93	50.5
	2020-Q2	118	80	67.8		2020-Q2	181	81	44.8
	2020-Q3	118	73	61.9		2020-Q3	177	76	42.9
	2020-Q4	116	74	63.8		2020-Q4	173	74	42.8
	2021-Q1	98	61	62.2		2021-Q1	146	62	42.5
	2021-Q2	86	56	65.1		2021-Q2	125	57	45.6
	2021-Q3	77	55	71.4		2021-Q3	121	58	47.9
	2021-Q4	75	54	72.0		2021-Q4	117	55	47
	2022-Q1	69	31	44.9		2022-Q1	106	32	30.2
	2022-Q2	64	43	67.2		2022-Q2	97	43	44.3
	2022-Q3	64	40	62.5		2022-Q3	93	40	43
	2022-Q4	55	40	72.7		2022-Q4	77	40	51.9
	2023-Q1	52	36	69.2		2023-Q1	90	37	41.1
	2023-Q2	52	30	57.7		2023-Q2	82	30	36.6
	2023-Q3	52	34	65.4		2023-Q3	76	34	44.7
	2023-Q4	39	23	59.0		2023-Q4	54	23	42.6
	2024-Q1	32	22	68.8		2024-Q1	52	22	42.3
	2024-Q2	30	21	70.0		2024-Q2	43	21	48.8

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
LOS Days (Term Babies)	2017-Q1	250	15.7		Higher Level care	2017-Q1	258	130	50.4
	2017-Q2	217	12.6			2017-Q2	220	90	40.9
	2017-Q3	200	14.6			2017-Q3	209	90	43.1
	2017-Q4	228	13.6			2017-Q4	237	101	42.6
	2018-Q1	209	14.1			2018-Q1	216	95	44.0
	2018-Q2	173	12.2			2018-Q2	175	68	38.9
	2018-Q3	172	12.8			2018-Q3	176	63	35.8
	2018-Q4	172	11.2			2018-Q4	174	47	27.0
	2019-Q1	177	13.0			2019-Q1	182	64	35.2
	2019-Q2	178	11.4			2019-Q2	178	58	32.6
	2019-Q3	165	11.3			2019-Q3	168	69	41.1
	2019-Q4	154	11.6			2019-Q4	157	54	34.4
	2020-Q1	139	10.7			2020-Q1	139	46	33.1
	2020-Q2	133	11.2			2020-Q2	137	44	32.1
	2020-Q3	132	11.6			2020-Q3	138	40	29.0
	2020-Q4	136	13.6			2020-Q4	139	56	40.3
	2021-Q1	116	12.0			2021-Q1	122	39	32.0
	2021-Q2	107	13.3			2021-Q2	107	50	46.7
	2021-Q3	101	13.1			2021-Q3	102	34	33.3
	2021-Q4	98	13.9			2021-Q4	101	31	30.7
	2022-Q1	86	11.6			2022-Q1	90	31	34.4
	2022-Q2	79	12.7			2022-Q2	80	34	42.5
	2022-Q3	74	13.3			2022-Q3	74	22	29.7
	2022-Q4	61	12.0			2022-Q4	62	16	25.8
	2023-Q1	72	11.8			2023-Q1	73	28	38.4
	2023-Q2	61	14.5			2023-Q2	62	23	37.1
	2023-Q3	62	13.4			2023-Q3	64	20	31.3
	2023-Q4	43	11.7			2023-Q4	44	17	38.6
	2024-Q1	34	13.6			2024-Q1	36	16	44.4
	2024-Q2	36	10.2			2024-Q2	36	13	36.1
	2024-Q3	19	7.6			2024-Q3	20	3	15.0

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
No Pharm Therapy LOS Days(Term Babies)	2017-Q1	103	6.5		Pharm Therapy LOS Days (Term Babies)	2017-Q1	147	22.2	
	2017-Q2	130	6.4			2017-Q2	87	21.9	
	2017-Q3	98	6.5			2017-Q3	102	22.5	
	2017-Q4	116	6.2			2017-Q4	112	21.3	
	2018-Q1	94	6.3			2018-Q1	114	20.5	
	2018-Q2	102	5.9			2018-Q2	71	21.3	
	2018-Q3	107	6.6			2018-Q3	63	23.7	
	2018-Q4	119	6.3			2018-Q4	52	22.4	
	2019-Q1	109	6.1			2019-Q1	64	25.0	
	2019-Q2	121	6.3			2019-Q2	55	22.4	
	2019-Q3	107	6.4			2019-Q3	58	20.3	
	2019-Q4	98	6.3			2019-Q4	55	21.3	
	2020-Q1	96	6.6			2020-Q1	42	20.0	
	2020-Q2	86	6.1			2020-Q2	46	20.9	
	2020-Q3	89	6.3			2020-Q3	40	23.2	
	2020-Q4	85	7.1			2020-Q4	50	24.9	
	2021-Q1	83	7.5			2021-Q1	33	23.4	
	2021-Q2	60	6.7			2021-Q2	47	21.8	
	2021-Q3	68	6.8			2021-Q3	32	26.7	
	2021-Q4	57	8.0			2021-Q4	40	22.3	
	2022-Q1	56	6.9			2022-Q1	28	21.5	
	2022-Q2	46	6.9			2022-Q2	33	20.7	
	2022-Q3	50	7.4			2022-Q3	24	25.5	
	2022-Q4	42	5.9			2022-Q4	19	25.6	
	2023-Q1	45	6.8			2023-Q1	27	20.2	
	2023-Q2	37	5.8			2023-Q2	24	28.0	
	2023-Q3	40	6.2			2023-Q3	22	26.5	
	2023-Q4	29	6.6			2023-Q4	14	22.2	
	2024-Q1	21	7.5			2024-Q1	13	23.5	
	2024-Q2	25	6.5			2024-Q2	11	18.5	
	2024-Q3	16	6.5			2024-Q3	2	18.5	

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
Number of Days on Pharm Therapy (Term Babies)	2017-Q1	139	16.6						
	2017-Q2	84	17.3						
	2017-Q3	100	17.2						
	2017-Q4	108	15.7						
	2018-Q1	109	15.2						
	2018-Q2	67	16.3						
	2018-Q3	62	18.1						
	2018-Q4	50	17.0						
	2019-Q1	63	19.1						
	2019-Q2	54	16.5						
	2019-Q3	56	14.4						
	2019-Q4	48	13.5						
	2020-Q1	39	14.5						
	2020-Q2	39	13.5						
	2020-Q3	36	16.7						
	2020-Q4	47	17.1						
	2021-Q1	33	17.2						
	2021-Q2	47	16.9						
	2021-Q3	30	19.3						
	2021-Q4	37	16.3						
	2022-Q1	28	16.9						
	2022-Q2	29	14.8						
	2022-Q3	22	16.8						
	2022-Q4	19	17.6						
	2023-Q1	26	14.2						
	2023-Q2	22	17.0						
	2023-Q3	19	17.9						
	2023-Q4	14	15.4						
	2024-Q1	10	14.4						
	2024-Q2	11	12.1						
	2024-Q3	2	14.5						

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
Referral to EI	2017-Q1	299	221	73.9	Referral to DCF	2017-Q1	317	311	98.1
	2017-Q2	252	176	69.8		2017-Q2	265	248	93.6
	2017-Q3	245	188	76.7		2017-Q3	259	251	96.9
	2017-Q4	280	212	75.7		2017-Q4	289	275	95.2
	2018-Q1	252	196	77.8		2018-Q1	261	250	95.8
	2018-Q2	217	140	64.5		2018-Q2	217	201	92.6
	2018-Q3	204	151	74.0		2018-Q3	205	191	93.2
	2018-Q4	205	145	70.7		2018-Q4	212	200	94.3
	2019-Q1	213	159	74.6		2019-Q1	226	212	93.8
	2019-Q2	211	160	75.8		2019-Q2	212	200	94.3
	2019-Q3	219	167	76.3		2019-Q3	221	206	93.2
	2019-Q4	183	136	74.3		2019-Q4	193	183	94.8
	2020-Q1	173	129	74.6		2020-Q1	184	171	92.9
	2020-Q2	181	143	79.0		2020-Q2	181	170	93.9
	2020-Q3	176	138	78.4		2020-Q3	177	167	94.4
	2020-Q4	162	119	73.5		2020-Q4	173	165	95.4
	2021-Q1	141	108	76.6		2021-Q1	148	139	93.9
	2021-Q2	113	89	78.8		2021-Q2	126	106	84.1
	2021-Q3	113	92	81.4		2021-Q3	124	107	86.3
	2021-Q4	113	80	70.8		2021-Q4	117	107	91.5
	2022-Q1	93	66	71.0		2022-Q1	103	94	91.3
	2022-Q2	89	66	74.2		2022-Q2	97	83	85.6
	2022-Q3	76	61	80.3		2022-Q3	92	76	82.6
	2022-Q4	71	58	81.7		2022-Q4	78	67	85.9
	2023-Q1	81	58	71.6		2023-Q1	89	77	86.5
	2023-Q2	72	63	87.5		2023-Q2	82	72	87.8
	2023-Q3	72	64	88.9		2023-Q3	76	71	93.4
	2023-Q4	48	36	75.0		2023-Q4	54	43	79.6
	2024-Q1	44	38	86.4		2024-Q1	52	38	73.1
	2024-Q2	40	37	92.5		2024-Q2	43	33	76.7
	2024-Q3	23	11	47.8		2024-Q3	23	19	82.6

Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)	Metric	Quarter	Sample Size	Numerator/ Mean	Percent (%)
Discharged Home with Biological Parent	2017-Q1	317	235	74.1					
	2017-Q2	266	206	77.4					
	2017-Q3	258	184	71.3					
	2017-Q4	286	214	74.8					
	2018-Q1	261	181	69.3					
	2018-Q2	217	165	76.0					
	2018-Q3	204	153	75.0					
	2018-Q4	210	163	77.6					
	2019-Q1	225	173	76.9	Plan of Safe Care	2019-Q1	225	61	27.1
	2019-Q2	212	145	68.4		2019-Q2	212	73	34.4
	2019-Q3	220	167	75.9		2019-Q3	220	53	24.1
	2019-Q4	195	142	72.8		2019-Q4	194	57	29.4
	2020-Q1	182	138	75.8		2020-Q1	183	75	41.0
	2020-Q2	179	130	72.6		2020-Q2	181	81	44.8
	2020-Q3	176	126	71.6		2020-Q3	176	87	49.4
	2020-Q4	171	127	74.3		2020-Q4	172	83	48.3
	2021-Q1	146	105	71.9		2021-Q1	148	68	45.9
	2021-Q2	126	89	70.6		2021-Q2	126	69	54.8
	2021-Q3	124	86	69.4		2021-Q3	121	63	52.1
	2021-Q4	119	79	66.4		2021-Q4	117	47	40.2
	2022-Q1	106	67	63.2		2022-Q1	105	51	48.6
	2022-Q2	97	65	67		2022-Q2	96	59	61.5
	2022-Q3	92	69	75		2022-Q3	91	44	48.4
	2022-Q4	77	55	71.4		2022-Q4	78	43	55.1
	2023-Q1	91	67	73.6		2023-Q1	91	57	62.6
	2023-Q2	83	52	62.7		2023-Q2	83	50	60.2
	2023-Q3	76	47	61.8		2023-Q3	76	55	72.4
	2023-Q4	53	40	75.5		2023-Q4	54	32	59.3
	2024-Q1	52	32	61.5		2024-Q1	52	35	67.3
	2024-Q2	43	32	74.4		2024-Q2	43	29	67.4
	2024-Q3	22	10	45.5		2024-Q3	23	8	34.8